Company intelligence / Profile preview

Visant Medical

Menlo Park, California, United Statesnordicpharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Visant Medical developed LACRIFILL, a cross-linked hyaluronic acid-based canalicular occlusive device for temporary blockage of tear drainage to treat dry eye disease. The product received FDA 510(k) clearance in 2022 and is indicated for up to six months' use in patients with dry eye symptoms. Clinical results highlight its comfort and effectiveness in managing dry eye by conserving tears

Therapeutic areas: Ophthalmology
Modalities: DeviceBiologic
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

LACRIFILL

Commercial

Indications: Dry eye disease

Partnerships

SYMATESE (co-developer/manufacturer of the hyaluronic acid gel technology)

Beyond the preview

Go deeper on Visant Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Visant Medical.

Explore the full profile